AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37823711 — intervention group
Group type: COMPARATOR
Intervention: Control group (ad libitum)
Number of subjects: 90
Study 33446270 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy followed by physiotherapeutic scoliosis-specific exercise (PSSE)
Number of subjects: 40
Study 33446270 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapeutic scoliosis-specific exercise (PSSE) alone
Number of subjects: 40
Study 32182615 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed vitrification system
Number of subjects: 190
Study 32182615 — intervention group
Group type: COMPARATOR
Intervention: Open vitrification system
Number of subjects: 190
Study 33589575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on 5 pivotal RBP genes (RNASE2, METTL1, ANG, YBX2, LARP6)
Number of subjects: 806
Study 33589575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram developed from the model
Number of subjects: 806
Study 32564920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 440 μg
Number of subjects: 592
Study 32564920 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal sirolimus 44 μg
Number of subjects: 592
Study 32564920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sirolimus 880 μg
Number of subjects: 592
Study 34403137 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation intervention with or without supplementation (n=48)
Number of subjects: 127
Study 34403137 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (no-intervention and supplementation only, n=47)
Number of subjects: 127
Study 34403137 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (children without stunted growth, n=64)
Number of subjects: 127
Study 33478563 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy (1 hour per day for 10 days)
Number of subjects: 19
Study 33478563 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care therapy only)
Number of subjects: 19
Study 35072431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam-propofol-sufentanil
Number of subjects: 0
Study 35072431 — intervention group
Group type: COMPARATOR
Intervention: Propofol-sufentanil
Number of subjects: 0
Study 33929533 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (16 weeks)
Number of subjects: 100
Study 33929533 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 36117971 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam with alfentanil (group RA)
Number of subjects: 100
Study 36117971 — intervention group
Group type: COMPARATOR
Intervention: Propofol with alfentanil (group PA)
Number of subjects: 100
Study 36117971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 35042638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone reminders (SMS and follow-up calls) sent three days to and on the due date of the child's schedule for the 1st, 2nd, and 3rd doses of the pentavalent vaccine.
Number of subjects: 541
Study 35042638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile phone reminders).
Number of subjects: 541
Study 34487764 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI) using ultra-hypofractionated radiation (UHRT) (25 Gy in 5 weekly fractions)
Number of subjects: 165
Study 616083505 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Betadine
Number of subjects: 20
Study 32907642 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) intervention
Number of subjects: 0
Study 32907642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33188398 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified orange-fleshed sweetpotato
Number of subjects: 59
Study 33188398 — intervention group
Group type: COMPARATOR
Intervention: Regular orange-fleshed sweetpotato
Number of subjects: 59
Study 33188398 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified purple-fleshed potato
Number of subjects: 59
Study 33188398 — intervention group
Group type: COMPARATOR
Intervention: Regular yellow-fleshed potato
Number of subjects: 59
Study 35260463 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 40
Study 35260463 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lignocaine
Number of subjects: 40
Study 33522839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin treatment
Number of subjects: 513
Study 33522839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin treatment
Number of subjects: 513
Study 33522839 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients
Number of subjects: 513
Study 33522839 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 513
Study 32649733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech with 0 dB SNR
Number of subjects: 8
Study 32649733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speech with -5 dB SNR
Number of subjects: 8
Study 36274805 — intervention group
Group type: EXPERIMENTAL
Intervention: USG-guided out-of-plane approach to right IJV cannulation
Number of subjects: 110
Study 36274805 — intervention group
Group type: COMPARATOR
Intervention: USG-guided supraclavicular in-plane approach to right BCV cannulation
Number of subjects: 110
Study 32035748 — intervention group
Group type: EXPERIMENTAL
Intervention: EchoEducator smartphone application
Number of subjects: 30
Study 32035748 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative teaching
Number of subjects: 30
Study 35275852 — intervention group
Group type: EXPERIMENTAL
Intervention: Braces with pressure points at the apical vertebra level
Number of subjects: 72
Study 35275852 — intervention group
Group type: EXPERIMENTAL
Intervention: Braces with ventral support
Number of subjects: 72
Study 35275852 — intervention group
Group type: EXPERIMENTAL
Intervention: Braces with upper straps positioned above T10
Number of subjects: 72
Study 35275852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral and ventral skin‐to‐brace pressures
Number of subjects: 72
Study 34146026 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydration (CH)
Number of subjects: 90
Study 34146026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior stromal pocket hydration (ASPH)
Number of subjects: 90
Study 34146026 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified stromal pocket hydration (MASH)
Number of subjects: 90
Study 34146026 — intervention group
Group type: COMPARATOR
Intervention: ASPH and MASH compared to CH
Number of subjects: 90
Study 34146026 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPH
Number of subjects: 90
Study 34146026 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 32842052 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 hormone therapy (TX-001HR)
Number of subjects: 1340
Study 32842052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1340
Study 34788454 — intervention group
Group type: EXPERIMENTAL
Intervention: Zao Ren An Shen (ZRAS) capsule
Number of subjects: 85
Study 34788454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 36377643 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Zika vaccine (6 antigen units)
Number of subjects: 67
Study 36377643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Zika vaccine (3 antigen units)
Number of subjects: 67
Study 36377643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32278858 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d of purified anthocyanins
Number of subjects: 111
Study 32278858 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of purified anthocyanins
Number of subjects: 111
Study 35965392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution, 0.25%
Number of subjects: 421
Study 35965392 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 421
Study 32838478 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab
Number of subjects: 5465
Study 32838478 — intervention group
Group type: EXPERIMENTAL
Intervention: ipinivo
Number of subjects: 5465
Study 32838478 — intervention group
Group type: EXPERIMENTAL
Intervention: nivolumab
Number of subjects: 5465
Study 32838478 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab
Number of subjects: 5465
Study 32916347 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES active on leg ipsilateral to SSEP acquisition
Number of subjects: 0
Study 32916347 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES active on leg contralateral to SSEP acquisition
Number of subjects: 0
Study 32916347 — intervention group
Group type: COMPARATOR
Intervention: Sham (NMES inactive)
Number of subjects: 0
Study 36477809 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class I
Number of subjects: 8326
Study 36477809 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class III
Number of subjects: 8326
Study 36477809 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class II
Number of subjects: 8326
Study 36477809 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class I with high NT-proBNP levels
Number of subjects: 8326
Study 33442904 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron infusion (iron (iii)-hydroxide sucrose)
Number of subjects: 20
Study 33442904 — intervention group
Group type: COMPARATOR
Intervention: Iron chelation (desferrioxamine)
Number of subjects: 20
Study 33442904 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 25% peak wattage
Number of subjects: 20
Study 32700220 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach-led intervention for chronic pain (6 months, contact twice per month)
Number of subjects: 215
Study 32700220 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-hour pain self-management class)
Number of subjects: 215
Study 32700220 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coach-led intervention
Number of subjects: 215
Study 32700220 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study 34263647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the Zhongji (RN3) acupoint for 10 minutes
Number of subjects: 72
Study 34263647 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture for 10 minutes
Number of subjects: 72
Study 33072197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin, 50 mL per day for ten days, followed by two treatment cycles with 10 mL per day for ten days
Number of subjects: 80
Study 33072197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 80
Study 36148451 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxlovid
Number of subjects: 142
Study 36148451 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 35419726 — intervention group
Group type: EXPERIMENTAL
Intervention: Guihuang Formula (GHF)
Number of subjects: 66
Study 35419726 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 66
Study 35419726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 33863716 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 135
Study 33863716 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (Control)
Number of subjects: 135
Study 36250147 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO+CHO
Number of subjects: 10
Study 36250147 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 10
Study 36250147 — intervention group
Group type: COMPARATOR
Intervention: CHO+CHO
Number of subjects: 10
Study 33987442 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic metal brackets
Number of subjects: 40
Study 33987442 — intervention group
Group type: COMPARATOR
Intervention: No brackets (Control)
Number of subjects: 40
Study 32752149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity interventions to limit gestational weight gain (GWG)
Number of subjects: 0
Study 32752149 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity interventions to limit GWG
Number of subjects: 0
Study 32752149 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal GWG recommendations based on pre-pregnancy BMI categories
Number of subjects: 0
Study 35120184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-occipital transcranial alternating current stimulation (tACS) - anti-phase
Number of subjects: 24
Study 35120184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-occipital transcranial alternating current stimulation (tACS) - in-phase
Number of subjects: 24
Study 35120184 — intervention group
Group type: COMPARATOR
Intervention: Fronto-occipital transcranial alternating current stimulation (tACS) - control
Number of subjects: 24
Study 35120184 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly assessments of Dizziness Handicap Inventory (DHI), MdDS Balance Rating Scale (MBRS), and Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 24
Study 33655352 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group A
Number of subjects: 390
Study 33655352 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria positive cases
Number of subjects: 390
Study 33655352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia prevalence
Number of subjects: 390
Study 33655352 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for malaria
Number of subjects: 390
Study 33655352 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall malaria prevalence
Number of subjects: 390
Study 32708991 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dairy Diet (HDD) (5–6 dairy portions per day)
Number of subjects: 46
Study 32708991 — intervention group
Group type: COMPARATOR
Intervention: Low-Dairy Diet (LDD) (≤1 dairy portion per day)
Number of subjects: 46
Study 35143644 — intervention group
Group type: COMPARATOR
Intervention: CsA/MPA
Number of subjects: 160
Study 35143644 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-Cy/CsA
Number of subjects: 160
Study 34383532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM)
Number of subjects: 230
Study 34383532 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 230
Study 32933775 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-ERm: etch-and-rinse + moist dentin
Number of subjects: 39
Study 32933775 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-ERd: etch-and-rinse + dry dentin
Number of subjects: 39
Study 32933775 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-Set: selective enamel etching
Number of subjects: 39
Study 32933775 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-SE: self-etch
Number of subjects: 39
Study 32933775 — intervention group
Group type: EXPERIMENTAL
Intervention: SU-ERm and SU-ERd
Number of subjects: 39
Study 36166463 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based ART
Number of subjects: 62
Study 36166463 — intervention group
Group type: COMPARATOR
Intervention: raltegravir-based ART
Number of subjects: 62
Study 34476783 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 38
Study 34476783 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 38
Study 36282051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional MMR vaccine
Number of subjects: 40
Study 36282051 — intervention group
Group type: COMPARATOR
Intervention: Intralesional PPD injections
Number of subjects: 40
Study 33331957 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pen tests (DPT)
Number of subjects: 40
Study 33331957 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual results (MR)
Number of subjects: 40
Study 33020098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) therapy for depression
Number of subjects: 0
Study 33932411 — intervention group
Group type: EXPERIMENTAL
Intervention: poly (I:C) treatment
Number of subjects: 0
Study 33932411 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative real-time PCR (qRT-PCR) analysis of immune response genes
Number of subjects: 0
Study 32390092 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 30
Study 32390092 — intervention group
Group type: COMPARATOR
Intervention: 0.243% sodium fluoride dentifrice
Number of subjects: 30
Study 32829966 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer telomeres
Number of subjects: 37688
Study 32829966 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37688
Study 33159796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (60, 40, 30, 20, 15, and 10 mg daily for 1 week each, followed by 5 mg daily for 18 weeks)
Number of subjects: 65
Study 33159796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as prednisolone)
Number of subjects: 65
Study 33159796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 65
Study 33159796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 32921501 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 313
Study 32921501 — intervention group
Group type: COMPARATOR
Intervention: Usual dose pitavastatin (2 mg/d)
Number of subjects: 313
Study 35022459 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Number of subjects: 76
Study 35022459 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ultrasound-guided transversus abdominis plane (TAP) block with 20 cc of ropivacaine 0.25%
Number of subjects: 76
Study 34217259 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Education intervention given by a Supported Education specialist
Number of subjects: 100
Study 34217259 — intervention group
Group type: COMPARATOR
Intervention: Support as usual plus advice from a trained staff member on potential supportive resources regarding studying with mental health problems
Number of subjects: 100
Study 36014954 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Nutrition Package (INP) through home visits
Number of subjects: 60
Study 36014954 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (Control group)
Number of subjects: 60
Study 33471039 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg/d
Number of subjects: 156
Study 33471039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 35545781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Paclitaxel + Carboplatin (Group B)
Number of subjects: 68
Study 35545781 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin (Group A)
Number of subjects: 68
Study 32413238 — intervention group
Group type: COMPARATOR
Intervention: Test product (5-mg olanzapine ODT)
Number of subjects: 48
Study 32413238 — intervention group
Group type: COMPARATOR
Intervention: Reference product (5-mg olanzapine ODT)
Number of subjects: 48
Study 36372657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored sleep health education (10 brief education modules)
Number of subjects: 678
Study 36372657 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 678
Study 33677520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hula-based intervention (n = 131)
Number of subjects: 263
Study 33677520 — intervention group
Group type: COMPARATOR
Intervention: Education-only waitlist control (n = 132)
Number of subjects: 263
Study 33170854 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Health Clinic Patient Satisfaction Questionnaire (PHC‐PSQ)
Number of subjects: 400
Study 34924332 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-emotional technique (NET)
Number of subjects: 112
Study 34924332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 33218372 — intervention group
Group type: EXPERIMENTAL
Intervention: Right leg landing
Number of subjects: 32
Study 33218372 — intervention group
Group type: EXPERIMENTAL
Intervention: Left leg landing
Number of subjects: 32
Study 33218372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic postural stability
Number of subjects: 32
Study 37258803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Sitagliptin + Metformin ER (10 mg + 100 mg + 1000 mg)
Number of subjects: 415
Study 37258803 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin + Metformin SR (100 mg + 1000 mg)
Number of subjects: 415
Study 37258803 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin + Metformin ER (10 mg + 1000 mg)
Number of subjects: 415
Study 33522698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU per day of vitamin D
Number of subjects: 60
Study 33522698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36260470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive resin-modified glass ionomer (ACTIVA BioACTIVE restorative)
Number of subjects: 50
Study 36260470 — intervention group
Group type: COMPARATOR
Intervention: Giomer hybrid composite (Beautifil Flow Plus)
Number of subjects: 50
Study 32975600 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) using SIR‐Spheres yttrium‐90 resin microspheres
Number of subjects: 200
Study 32735216 — intervention group
Group type: EXPERIMENTAL
Intervention: BroHealth web‐based mental health program with BroMatters website access
Number of subjects: 77
Study 32735216 — intervention group
Group type: EXPERIMENTAL
Intervention: BroHealth web‐based mental health program with BroMatters website access and telephone sessions with a life coach
Number of subjects: 77
Study 32735216 — intervention group
Group type: EXPERIMENTAL
Intervention: HardHat web‐based mental health program
Number of subjects: 77
Study 32735216 — intervention group
Group type: COMPARATOR
Intervention: General depression information from BroMatters website
Number of subjects: 77
Study 32735216 — intervention group
Group type: COMPARATOR
Intervention: HardHat web‐based mental health program (post-RCT access)
Number of subjects: 77
Study 33932394 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of 5 μg.mL‐1 sufentanil (group S) with 30 mL of 0.5% bupivacaine
Number of subjects: 40